echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > J Hematol Oncol: Serological responses to SARS-COV2 vaccine in cancer patients

    J Hematol Oncol: Serological responses to SARS-COV2 vaccine in cancer patients

    • Last Update: 2022-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: With the ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the world has ushered in another year of global health emergencies
    .


    Extensive research over the past year has shown that older patients and those with pre-existing conditions such as obesity, diabetes and cancer are more likely to contract SARS-CoV-2 and develop life-threatening pneumonia


    The world has ushered in another year of global health emergency as the 2019 coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), persists


    Patients with hematological cancers had a higher case fatality rate (CFR) compared with patients with solid cancers (37% vs.


    OBJECTIVE: Cancer patients have an increased risk of coronavirus disease 2019 (COVID-19) and reduced responses to various vaccines
    .


    This meta-analysis aimed to assess the serological response to COVID-19 vaccination in cancer patients


    METHODS: Electronic databases were systematically searched on 1 August 2021 for studies reporting serologic responses to COVID-19 vaccines in cancer patients
    .


    A random-effects model was used to achieve pooled serological response rates and odds ratios (ORs)


    Results: We analyzed 16 observational studies with a total of 1453 cancer patients
    .


    Most studies used mRNA vaccines (BNT162b2 or mRNA-1273)


    Figure 1 Meta-analysis of serological responses after one dose of vaccine
    .


    B Meta-analysis of serological responses after two doses of vaccine

    Figure 1 Meta-analysis of serological responses after one dose of vaccine


    Figure 2.
    Meta-analysis of serological responses after one dose of vaccine compared with controls
    .


    B Meta-analysis of serological responses after two doses of vaccine compared with controls

    Figure 2.


    Cancer patients, especially those with hematological B-cell malignancies, have low serological responses to the COVID-19 vaccine


    Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis.
    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.